Birch pollen allergy vaccine tablet - ALK-Abello

Drug Profile

Birch pollen allergy vaccine tablet - ALK-Abello

Alternative Names: ALK-Tree-AIT; Betula Verrucosa allergen extract; Oralgen Birch Pollen; SLIT birch pollen extract; SLITone Birch; SLITonePLUS Birch; SQ tree SLIT-tablet

Latest Information Update: 15 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ALK-Abello
  • Class Allergens; Antiallergics; Peptide vaccines; Peptides; Tree pollen allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Allergic rhinoconjunctivitis

Most Recent Events

  • 14 Sep 2017 ALK-Abello announces intention to submit regulatory applications in the EU and Canada for Allergic rhinoconjunctivitis in 2018
  • 14 Sep 2017 Efficacy and safety data from a phase III trial in Allergic rhinoconjunctivitis released by ALK-Abello
  • 14 Sep 2017 ALK-Abello completes a phase III trial in Allergic rhinoconjunctivitis (In adolescents, In adults) in Sweden, Czech Republic, France, Denmark, Poland, Finland and Germany (Sublingual)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top